Nanobiotix Secures $100M in Global Offering as Underwriters Fully Exercise Over-Allotment Option
NBTX has more than doubled off its 52-week low of $3.64.
Summary
Nanobiotix announced the full exercise of the underwriters' over-allotment option, bringing the total gross proceeds from its global offering to approximately $100 million. This follows the May 21st announcement of the offering's pricing, which initially raised $98.6 million. This significant capital raise is expected to extend Nanobiotix's cash runway into 2029, reducing immediate financing risk for the late-clinical stage biotech. The funds will primarily advance its Nanoprimer and other platforms.
At the time of this announcement, NBTX was trading at $41.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $3.64 to $57.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.